Targeting sarcomas: therapeutic targets and their rational

Seminars in Diagnostic Pathology

Volumn 25, Issue 4, 2008, Pages 304-316

  Ordóñez, José Luis ^a   Martins, Ana Sofia ^a   Osuna, Daniel ^a   Madoz Gúrpide, Juan ^a   de Alava, Enrique ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cancer stem cells; Drug; Ewing's sarcoma; Sarcomas; Targeted therapy

Indexed keywords

ANTHRACYCLINE; AP 23573; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; CP 751871; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; HEAT SHOCK PROTEIN 90; IFOSFAMIDE; IMATINIB; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; RAPAMYCIN; SEMAXANIB; SOMATOMEDIN C RECEPTOR; STA 4783; STEM CELL FACTOR RECEPTOR; TANESPIMYCIN; TAXANE DERIVATIVE; TEMSIROLIMUS; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; U 6668; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER RESEARCH; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CHROMOSOME TRANSLOCATION; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EWING SARCOMA; GENE FUSION; GENETIC IDENTIFICATION; HIGH THROUGHPUT SCREENING; HISTOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MESENCHYMOMA; MONOTHERAPY; MYXOSARCOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SOFT TISSUE SARCOMA; SURVIVAL RATE; TARGET CELL; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASTIC STEM CELLS; SARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 53749094926     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2008.07.005     Document Type: Article

References (133)

1. Wunder J.S., Nielsen T.O., Maki R.G., et al. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8 (2007) 513-524
2. Magenau J.M., and Schuetze S.M. New targets for therapy of sarcoma. Curr Opin Oncol 20 (2008) 400-406
3. Hartmann J.T. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs 18 (2007) 245-254
4. Milano A., Apice G., Ferrari E., et al. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol 59 (2006) 74-84
5. Casali P.G., Jost L., Sleijfer S., et al. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 suppl 2 (2008) ii89-ii93
6. Maki R.G., Wathen J.K., Patel S.R., et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25 (2007) 2755-2763
7. Schoffski P., Dumez H., Wolter P., et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 9 (2008) 1609-1618
8. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D 7 (2006) 317-328
9. Garcia-Carbonero R., Supko J.G., Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 (2004) 1480-1490
10. Schoffski P., Wolter P., Clement P., et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 3 (2007) 381-392
11. Grosso F., Jones R.L., Demetri G.D., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8 (2007) 595-602
12. Scotlandi K., and Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 20 (2008) 419-427
13. Martins A.S., Mackintosh C., Martin D.H., et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 12 (2006) 3532-3540
14. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9 (2005) 753-768
15. De Meyts P., and Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1 (2002) 769-783
16. Savage S.A., Woodson K., Walk E., et al. Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev 16 (2007) 1667-1674
17. Feng Y., and Dimitrov D.S. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Dev 11 (2008) 178-185
18. Do I., Araujo E.S., Kalil R.K., et al. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Pathol Res Pract 203 (2007) 127-134
19. Gonzalez I., Andreu E.J., Panizo A., et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 10 (2004) 751-761
20. Bond M., Bernstein M.L., Pappo A., et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 50 (2008) 254-258
21. McArthur G.A., Demetri G.D., van Oosterom A., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23 (2005) 866-873
22. Cebe-Suarez S., Zehnder-Fjallman A., and Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63 (2006) 601-615
23. D'Adamo D.R., Anderson S.E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23 (2005) 7135-7142
24. Heymach J.V., Desai J., Manola J., et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10 (2004) 5732-5740
25. Jiang B.H., and Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat (2008) (in press)
26. Wan X., and Helman L.J. The biology behind mTOR inhibition in sarcoma. Oncologist 12 (2007) 1007-1018
27. Vojtechova M., Tureckova J., Kucerova D., et al. Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10 (2008) 99-107
28. Nielsen T.O., West R.B., Linn S.C., et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359 (2002) 1301-1307
29. Tschoep K., Kohlmann A., Schlemmer M., et al. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63 (2007) 111-124
30. Nielsen T.O., Hsu F.D., O'Connell J.X., et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 163 (2003) 1449-1456
31. Gehrmann M. Drug evaluation: STA-4783-enhancing taxane efficacy by induction of Hsp70. Curr Opin Invest Drugs 7 (2006) 574-580
32. Berkenblit A., Eder Jr. J.P., Ryan D.P., et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 13 (2007) 584-590
33. Hiscott P., Paraoan L., Choudhary A., et al. Thrombospondin 1, thrombospondin 2 and the eye. Prog Retin Eye Res 25 (2006) 1-18
34. Ordonez J.L., Paraoan L., Hiscott P., et al. Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma. Melanoma Res 15 (2005) 495-502
35. Kopp H.G., Patel S., Brucher B., et al. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol 9 (2008) 207-217
36. Rusk A., McKeegan E., Haviv F., et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics. ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 12 (2006) 7444-7455
37. Bersani F., Taulli R., Accornero P., et al. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer 44 (2008) 876-884
38. Lu G., Punj V., and Chaudhary P.M. Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 7 (2008) 603-608
39. Maki R.G., Kraft A.S., Scheu K., et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103 (2005) 1431-1438
40. Nakamura T., Tanaka K., Matsunobu T., et al. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 31 (2007) 803-811
41. Bailly R.A., Bosselut R., Zucman J., et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 14 (1994) 3230-3241
42. May W.A., Gishizky M.L., Lessnick S.L., et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 90 (1993) 5752-5756
43. May W.A., Lessnick S.L., Braun B.S., et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13 (1993) 7393-7398
44. Delattre O., Zucman J., Melot T., et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331 (1994) 294-299
45. de Alava E., Kawai A., Healey J.H., et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16 (1998) 1248-1255
46. Zoubek A., Dockhorn-Dworniczak B., Delattre O., et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?. J Clin Oncol 14 (1996) 1245-1251
47. Zwerner J.P., Joo J., Warner K.L., et al. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 27 (2008) 3282-3291
48. Rorie C.J., Thomas V.D., Chen P., et al. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 64 (2004) 1266-1277
49. Zwerner J.P., and May W.A. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 20 (2001) 626-633
50. Matsumoto Y., Tanaka K., Nakatani F., et al. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br J Cancer 84 (2001) 768-775
51. Dauphinot L., De Oliveira C., Melot T., et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 20 (2001) 3258-3265
52. Hahm K.B., Cho K., Lee C., et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 23 (1999) 222-227
53. Im Y.H., Kim H.T., Lee C., et al. EWS-FLI1. EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Cancer Res 60 (2000) 1536-1540
54. Nakatani F., Tanaka K., Sakimura R., et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 278 (2003) 15105-15115
55. Fukuma M., Okita H., Hata J., et al. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 22 (2003) 1-9
56. Prieur A., Tirode F., Cohen P., et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24 (2004) 7275-7283
57. Mendiola M., Carrillo J., Garcia E., et al. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 118 (2006) 1381-1389
58. Toretsky J.A., Connell Y., Neckers L., et al. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 31 (1997) 9-16
59. Tanaka K., Iwakuma T., Harimaya K., et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 99 (1997) 239-247
60. Asami S., Chin M., Shichino H., et al. Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle. Biol Pharm Bull 31 (2008) 391-394
61. Kovar H., Aryee D.N., Jug G., et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 7 (1996) 429-437
62. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65 (2005) 8984-8992
63. Bozzi F., Tamborini E., Negri T., et al. Evidence for activation of KIT. PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer 109 (2007) 1638-1645
64. Carrillo J., Garcia-Aragoncillo E., Azorin D., et al. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 13 (2007) 2429-2440
65. Brazil D.P., Park J., and Hemmings B.A. PKB binding proteins. Getting in on the Akt. Cell 111 (2002) 293-303
66. Hill M.M., and Hemmings B.A. Inhibition of protein kinase B/Akt implications for cancer therapy. Pharmacol Ther 93 (2002) 243-251
67. Hill M.M., and Hemmings B.A. Analysis of protein kinase B/Akt. Methods Enzymol 345 (2002) 448-463
68. Peruzzi F., Prisco M., Dews M., et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19 (1999) 7203-7215
69. Benini S., Manara M.C., Cerisano V., et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 108 (2004) 358-366
70. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
71. Kreuter M., Paulussen M., Boeckeler J., et al. Clinical significance of vascular endothelial growth factor-A expression in Ewing's sarcoma. Eur J Cancer 42 (2006) 1904-1911
72. Guan H., Zhou Z., Wang H., et al. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11 (2005) 2662-2669
73. Dalal S., Berry A.M., Cullinane C.J., et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 11 (2005) 2364-2378
74. Ullrich A., Gray A., Tam A.W., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5 (1986) 2503-2512
75. Pedrini M.T., Giorgino F., and Smith R.J. cDNA cloning of the rat IGF I receptors: structural analysis of rat and human IGF I and insulin receptors reveals differences in alternative splicing and receptor-specific domain conservation. Biochem Biophys Res Commun 202 (1994) 1038-1046
76. Scotlandi K., Benini S., Sarti M., et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 56 (1996) 4570-4574
77. Mateo-Lozano S., Tirado O.M., and Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 22 (2003) 9282-9287
78. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004) 221-230
79. Strammiello R., Benini S., Manara M.C., et al. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm Metab Res 35 (2003) 675-684
80. Garcia-Echeverria C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 (2004) 231-239
81. Scotlandi K., Manara M.C., Nicoletti G., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65 (2005) 3868-3876
82. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I receptor kinase inhibitor. NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 11 (2005) 1563-1571
83. Toretsky J.A., Kalebic T., Blakesley V., et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272 (1997) 30822-30827
84. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 3 (2004) 527-535
85. Camirand A., and Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 90 (2004) 1825-1829
86. Lacy M.Q., Alsina M., Fonseca R., et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor Type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26 (2008) 3196-3203
87. Ludwig J.A. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 20 (2008) 412-418
88. Fellinger E.J., Garin-Chesa P., Triche T.J., et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 139 (1991) 317-325
89. Weidner N., and Tjoe J. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 18 (1994) 486-494
90. Scotlandi K., Baldini N., Cerisano V., et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 60 (2000) 5134-5142
91. Scotlandi K., Perdichizzi S., Bernard G., et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer 42 (2006) 91-96
92. Cerisano V., Aalto Y., Perdichizzi S., et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 23 (2004) 5664-5674
93. Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem Sci 24 (1999) 136-141
94. Leppa S., and Sistonen L. Heat shock response-pathophysiological implications. Ann Med 29 (1997) 73-78
95. Zhang H., and Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82 (2004) 488-499
96. Thomas X., Campos L., Mounier C., et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 29 (2005) 1049-1058
97. Solit D.B., Basso A.D., Olshen A.B., et al. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63 (2003) 2139-2144
98. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5 (2005) 761-772
99. Jackson S.E., Queitsch C., and Toft D. Hsp90: from structure to phenotype. Nat Struct Mol Biol 11 (2004) 1152-1155
100. Martins A.S., Ordoñez J.L., García-Sánchez A., et al. A pivotal role for heat shock protein 90 in Ewing Sarcoma resistance to anti-IGF1R treatment: in vitro and in vivo study. Cancer Res 68 (2008) 6260-6270
101. Bagatell R., Gore L., Egorin M.J., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13 (2007) 1783-1788
102. Weigel B.J., Blaney S.M., Reid J.M., et al. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 13 (2007) 1789-1793
103. Ramalingam S.S., Egorin M.J., Ramanathan R.K., et al. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with Paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 14 (2008) 3456-3461
104. Modi S., Stopeck A.T., Gordon M.S., et al. Combination of trastuzumab and tanespimycin (17-AAG. KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25 (2007) 5410-5417
105. Baird K., Davis S., Antonescu C.R., et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65 (2005) 9226-9235
106. Castillero-Trejo Y., Eliazer S., Xiang L., et al. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 65 (2005) 8698-8705
107. Riggi N., Cironi L., Provero P., et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65 (2005) 11459-11468
108. Riggi N., Cironi L., Provero P., et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 66 (2006) 7016-7023
109. Riggi N., Suva M.L., Suva D., et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68 (2008) 2176-2185
110. Funes J.M., Quintero M., Henderson S., et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 104 (2007) 6223-6228
111. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiating human melanomas. Nature 451 (2008) 345-349
112. Hochhaus A., and Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 18 (2004) 641-656
113. Komuro H., Saihara R., Shinya M., et al. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J Pediatr Surg 42 (2007) 2040-2045
114. Bhatia R., Holtz M., Niu N., et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101 (2003) 4701-4707
115. Polyak K., and Hahn W.C. Roots and stems: stem cells in cancer. Nat Med 12 (2006) 296-300
116. Matushansky I., Hernando E., Socci N.D., et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117 (2007) 3248-3257
117. Taubert H., Wurl P., Greither T., et al. Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene 26 (2007) 7170-7174
118. Dingli D., and Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 24 (2006) 2603-2610
119. Gygi S.P., Rochon Y., Franza B.R., et al. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19 (1999) 1720-1730
120. Lu P., Vogel C., Wang R., et al. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 25 (2007) 117-124
121. Aebersold R., and Mann M. Mass spectrometry-based proteomics. Nature 422 (2003) 198-207
122. Yates III J.R., Gilchrist A., Howell K.E., et al. Proteomics of organelles and large cellular structures. Nat Rev Mol Cell Biol 6 (2005) 702-714
123. Ong S.E., and Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 1 (2005) 252-262
124. Cox J., and Mann M. Is proteomics the new genomics?. Cell 130 (2007) 395-398
125. Kang J.H., Park K.K., Lee I.S., et al. Proteome analysis of responses to ascochlorin in a human osteosarcoma cell line by 2-D gel electrophoresis and MALDI-TOF MS. J Proteome Res 5 (2006) 2620-2631
126. Li Z., Kreutzer M., Mikkat S., et al. Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death. Proteomics 6 (2006) 5735-5745
127. Izbicka E., Campos D., Marty J., et al. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res 26 (2006) 1983-1988
128. Gazziola C., Cordani N., Carta S., et al. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells. Int J Oncol 26 (2005) 129-140
129. Zanini C., Giribaldi G., Mandili G., et al. Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing's sarcoma cell lines. J Neurochem 103 (2007) 1344-1354
130. Hosokawa N., Hirayoshi K., Kudo H., et al. Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol Cell Biol 12 (1992) 3490-3498
131. Nagai N., Nakai A., and Nagata K. Quercetin suppresses heat shock response by down regulation of HSF1. Biochem Biophys Res Commun 208 (1995) 1099-1105
132. Kovar H., Aryee D., and Zoubek A. The Ewing family of tumors and the search for the Achilles' heel. Curr Opin Oncol 11 (1999) 275-284
133. Cohen P. The regulation of protein function by multisite phosphorylation-a 25 year update. Trends Biochem Sci 25 (2000) 596-601